Stockwinners Market Radar for June 11, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:03 EDT PepsiCo Chief Commercial Officer to step down - In a regulatory filing, PepsiCo announced that on June 5th, the company's Global Chief Commercial Officer Laxman Narasimhan notified the company of his intent to resign effective July 1, 2019.

19:14 EDT Occidental Petroleum chairman Batchelder buys 9.1K shares of common stock - In a regulatory filing, Occidental Petroleum disclosed that its non-executive chairman Eugene Batchelder bought 9.1K shares of common stock on June 10th. The total transaction size was $438K.

18:57 EDT EQT Corporation CEO: Rice Team claims are not based on reality - In an interview on CNBC's Mad Money, EQT Corporation CEO Robert McNally said: It has been a tough time for natural gas operators, but we have materially outperformed our peers recently... We have downsized the company and have been pushing a cultural change... We have cut $150M of costs from the system... We have the potential to be the low cost producer and that is a goal of ours.

18:34 EDT Tesla CEO Musk says 'feel good about demand' - Says profitability is "always challenging for a growth company". Says "we can be cash flow positive despite having a very high growth rate."

18:22 EDT Tableau CEO: We are all about choice and flexibility - In an interview on CNBC's Mad Money, Tableau CEO Adam Selipsky said: Tableau (DATA) will run independently of Salesforce (CRM).... My whole executive team will be on board after the acquisition... The all-stock deal is a great way to participate in Salesforce's success... We will each have our own customers to introduce to eachother... It will be magic if we can bring them together... There is already a long and impressive list of joint customers between Tableau and Salesforce.

18:05 EDT Microsoft's Hogan sells 15,947 common shares - In a regulatory filing, Microsoft executive VP of Human Resources Kathleen T. Hogan disclosed the sale of 15,947 common shares of the company at a price of $133.1695 per share.

18:00 EDT GSV Capital CEO Mark Klein purchases 30K shares of company stock - GSV Capital CEO Mark Klein purchased 30,000 shares of company stock at an average price of $6.44 per share between June 10 and June 11. The total transaction value of the purchase was $193,260.

17:57 EDT GSV Capital CEO Mark Klein purchased 30K shares of company stock - GSV Capital CEO Mark Klein purchased 30,000 shares of company stock at an average price of $6.44 per share between June 10 and June 11. The total transaction value of the purchase was $193,260.

17:38 EDT FuelCell delays filing 10-Q for Q2 as company explores refinancing alternatives - In a regulatory NT 10-Q filing, FuelCell says it is delaying filing Form 10-Q for the three months ended April 30, 2019. The delay in filing is "due to the company's ongoing process of exploring refinancing alternatives and negotiations with its senior lender, the recent changes in the company's management and the related consideration of any updates to the company's internal controls which may be required as a result of those changes, and management's continuing review, analysis and assessment of certain financial and other related data."

17:19 EDT Lyft launches new electric-assist bicycles for its Bay Area bikeshare programs - Lyft said on its blog: "Big news for anyone who wants to get around the Bay Area on two wheels: Today, the Ford GoBike system has a new name - Bay Wheels. We're also launching a brand-new ebike that you can access with just two taps in the Lyft app. We've been working for many months on this new hybrid ebike and are thrilled to finally debut it in the Bay Area. It has brand new features that will make bikeshare better than ever - such as pedal-assist for those infamous hills, plus a new lock that will let you park outside of a station. Riders in San Jose will see these new ebikes starting today. We're working to add them to our fleets in San Francisco and the East Bay in the coming weeks. We're partnering with renowned Bay Area artists to transform the classic blue GoBikes into pieces of mobile art. Below, you can check out our collaboration with Oakland-based artist Hueman." Reference Link

17:10 EDT FTE Networks receives noncompliance notice from NYSE American - FTE Networks, Inc. announced that on June 5, 2019, the company received a notice of non-compliance from the NYSE Regulation staff of the New York Stock Exchange. As previously disclosed on the company's Form 8-K filed on June 3, 2019, four of the members of the board of directors of FTE Networks, Inc. resigned effective May 30, 2019. On May 30, 2019, the Company notified NYSE that, following the resignations, the company had only one independent director, that he was the only member of the Audit Committee and that there were no members on the Nominating Committee and Compensation Committee. As a result, NYSE sent the company a letter dated June 5, 2019 advising the company that it was no longer in compliance with NYSE's continued listing requirements set forth in Part 8 of the NYSE American Company guide. Specifically, after giving effect to the board and respective committee resignations, NYSE informed the company that: the company's Audit Committee was no longer compliant with Section 803B2c of the Company Guide as it was no longer composed of two independent members; the company's Nominating Committee was no longer compliant with the requirements set forth in Section 804 of the Company Guide; and the company's Compensation Committee was no longer compliant with the requirements set forth in Section 805a of the Company Guide.

17:07 EDT First Horizon to unify its brands - First Horizon announced that it will bring together its family of companies under a unified set of brand names and a new logo. In the fall, Capital Bank, First Tennessee Bank, FTB Advisors, and FTN Financial will become First Horizon Bank, First Horizon Advisors and FHN Financial, respectively. In fall 2019, the brand will be introduced through an advertising campaign, rebranding of financial centers, corporate buildings, and customer communication channels.

17:02 EDT Cardiovascular Systems announces enrollment of first patient in REACH PVI study - Cardiovascular Systems announced the first patient was enrolled in the REACH PVI study. The purpose of this study is to prospectively evaluate acute clinical outcomes of orbital atherectomy via transradial access for the treatment of peripheral artery disease in lower extremity lesions. REACH PVI is a prospective, observational, single-arm, multi-center post-market study that will enroll 50 patients at up to 10 sites across the United States. The purpose of this study is to prospectively evaluate acute clinical outcomes of orbital atherectomy via transradial access for treatment of peripheral artery disease in lower extremity lesions.

17:01 EDT CPSC says Amazon recalls about 377,000 space heaters due to fire hazards - The CPSC said that Amazon is recalling about 377,000 AmazonBasics Ceramic Space Heaters due to fire and burn hazards. The heaters are being recalled as they can overheat, posing fire and burn hazards, according to the CPSC. Amazon received 25 reports in the United States and 5 reports in Canada of the ceramic heater overheating, burning, or sparking. Two of those reports included minor damage to power outlets. There were no injuries associated with the incidents. No incidents were reported in Mexico.

16:42 EDT Twitter Developer Labs releases new versions of core API endpoints - Twitter said its releasing New versions of core API endpoints provide a foundation for working with the Twitter API. Look up Tweets and users by ID. "Be the first to know when we release early versions of new endpoints and features in Twitter Developer Labs. We'll send occasional promotional emails to keep you informed and ask for product feedback," said Twitter in a posing to its Developer Labs website. Reference Link

16:31 EDT FMC Corporation names Ronaldo Pereira president of Americas region - FMC Corporation announced that it is realigning the leadership structure for its North America and Latin America regions. Ronaldo Pereira, president, FMC Latin America, has been appointed president of the company's new Americas Region, which encompasses the U.S., Canada, Central America and South America. Pereira will continue to report to Mark Douglas, FMC president and chief operating officer. Due to this leadership realignment, Amy O'Shea, vice president and business director for North America, will leave the organization to pursue other opportunities. Pereira began his career at FMC in 1995 and has held a variety of marketing, business development and general management roles in Latin America and at the global level.

16:25 EDT Royal Dutch Shell unit in pact to sell Martinez Refinery to PBF unit for $1B + - Equilon Enterprises, a subsidiary of Royal Dutch Shell (RDS.A) announced it has reached an agreement for the sale of Shell's Martinez Refinery in California to PBF Holding Company, a subsidiary of PBF Energy (PBF) for $1B consideration plus the value of hydrocarbon inventory, crude oil supply and product offtake agreements, and other adjustments. This divestment aligns with Shell's strategy to reshape refining efforts towards a smaller, smarter refining portfolio focused on further integration with Shell Trading hubs, Chemicals, and Marketing. "This deal is another step in our transformation to high-grade and optimize our portfolio to drive resilient returns," said Shell's Downstream Director, John Abbott. The transaction is subject to closing conditions and regulatory approvals and is expected to close in 2019.

16:18 EDT Artisan Partners reports AUM $106.9B as of May 31 - Separate accounts accounted for $56B of total firm AUM, while Artisan Funds and Artisan Global Funds accounted for $50.9B.

16:17 EDT Interpublic Group announces CFO transition - Interpublic Group announced that Frank Mergenthaler, executive VP and CFO, has elected to retire effective December 31. Mergenthaler will continue with the company in an advisory role through March 31, 2020. Ellen Johnson, currently the company's senior VP of Finance and Treasurer, and Global CFO of IPG Mediabrands, will succeed Mergenthaler, to become Interpublic's executive VP and CFO on January 1, 2020.

16:16 EDT Invesco reports preliminary AUM $1.16T as of May 31 - An increase of 18.9%. The increase was driven by the OppenheimerFunds combination, modest net long-term inflows and reinvested distributions, partially offset by unfavorable market returns, lower money market AUM, foreign exchange, and non-management fee earning AUM outflows. FX decreased AUM by $3.7B.

16:13 EDT Emerson CMO Button sells 15,791 common shares - In a regulatory filing, Emerson Electronic chief marketing officer Bell Katherine Button disclosed the sale of 15,791 common shares of the company at a price of $63.9061 per share.

16:10 EDT MagnaChip up 13.4% to $10.01 after raising Q2 guidance

16:09 EDT Nuvectra files regulatory submission with FDA for Algovita SCS system - Nuvectra announced that it has filed its regulatory submission with the FDA for full-body MR-conditional approval for the company's Algovita SCS system. This submission, pending regulatory approval from the FDA, would position the company to achieve MR-conditional approval at or around year end following a 180-day review process.

16:05 EDT Neurocrine to present data showing 'opicapone was generally well tolerated' - Neurocrine announced it will present data from two of its movement disorder programs, including INGREZZA capsules, the first U.S. FDA approved treatment for adults with tardive dyskinesia, and opicapone, an investigational adjunct treatment for Parkinson's disease. Analyses include long-term data on INGREZZA in adult patients with TD, a disorder characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients. In addition, pooled analyses of opicapone will be highlighted, including efficacy data and new safety and tolerability data from two pivotal studies in more than 500 Parkinson's disease patients with motor fluctuations. The data will be presented at the 2019 World Congress on Parkinson's Disease and Related Disorders in Montreal, June 16-19. "We look forward to sharing six clinical presentations from our movement disorder programs, including long-term data showing sustained clinical benefit of INGREZZA in patients with tardive dyskinesia. In addition, we will share Phase III data analyses in Parkinson's disease demonstrating that opicapone was generally well tolerated and prolonged the clinical effect of levodopa, resulting in a significant reduction of OFF time in patients with Parkinson's disease," said Eiry Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "With INGREZZA, it is our goal to provide patients with an effective long-term treatment option to manage the uncontrollable movements of tardive dyskinesia, which can often cause isolation in patients. In patients with Parkinson's disease, we aim to provide a new treatment option to help manage motor fluctuations and better control the effects of this chronic, debilitating disease."

16:03 EDT Origin Agritech receive non-compliance letter from NASDAQ - Origin Agritech announced that on June 5 the Company received a letter from the NASDAQ Stock Market notifying the Company that the Company is not in compliance with the NASDAQ listing rules. The Company's Form 20-F for the FY19 reported stockholders' equity of ($3,396,000) and therefore, the Company is not in compliance with NASDAQ Listing Rule 5450 which requires the Company to maintain a minimum of $10,000,000 in stockholders' equity. The Company has 45 calendar days to submit a plan to NASDAQ to regain compliance and if such plan is accepted, the Company can be granted an extension of up to 180 calendar days from the Notice Date to evidence compliance. If NASDAQ does not accept the Company's plan, the Company will have the opportunity to appeal that decision to a hearings panel. The Company's management is pursuing options to address the noncompliance and intends to submit a compliance plan on or before the deadline set

15:47 EDT Eros falls 12% after Moody's downgrade on 'strained liquidity profile' - Shares of Eros International are moving lower after Moody's this morning downgraded the Corporate Family Rating for the company to B2 from B1. Moody's also changed Eros International's outlook to negative from stable. "The rating downgrade reflects Eros Plc's strained liquidity profile, which led to delays in servicing the bank loans of its Indian subsidiary, Eros International Media India Limited," said Nidhi Dhruv, a Moody's Vice President and Senior Analyst, in a press release. Shares of Eros are down 12%, or 39c, to $2.76 in afternoon trading.

15:34 EDT PTC announces new initiatives to grow its AR business - PTC announced new initiatives to grow its AR business and strengthen its Vuforia Augmented Reality platform. These initiatives include enhanced 3D AR model targets, leveraging Azure Spatial Anchor Services, a strategic collaboration with Matterport to further the PTC enterprise reach into factories and other spaces, and the acquisition of a world-class AR services agency, TWNKLS. "AR redefines how the enterprise works. Across all industrial use cases including manufacturing, engineering, service and training, AR is improving productivity, reducing waste, and increasing worker safety and compliance. AR empowers organizations to digitally transform their products, processes, and people," said Jim Heppelmann, president and CEO, PTC. "Our strategic alliances, acquisitions, and groundbreaking technology highlight PTC's commitment to helping industrial companies succeed with their digital transformation initiatives."

14:50 EDT Novo Nordisk says oral semaglutide showed cardiovascular safety in PIONEER 6 - Novo Nordisk announced that the PIONEER 6 trial achieved its primary endpoint by demonstrating non-inferiority of major adverse cardiovascular events, or MACE, with oral semaglutide compared with placebo, both in addition to standard of care. The primary endpoint was defined as the MACE composite outcome of the first occurrence of cardiovascular death, non-fatal myocardial infarction or non-fatal stroke and non-inferiority for cardiovascular safety of oral semaglutide versus placebo was confirmed with a hazard ratio of 0.79 in favor of oral semaglutide compared with placebo. The results are based on an accumulation of 137 first major adverse cardiovascular events and a median follow-up time of 16 months. The main results from PIONEER 6 were presented today at the American Diabetes Association 79th Scientific Sessions and simultaneously published in The New England Journal of Medicine.

14:05 EDT Broadridge VP Robert Kalenka sells over $1M in company shares - Broadridge VP Robert Kalenka disclosed in a filing that he had sold 8,000 shares of company stock at an average price of $132.58 per share on June 10. The total transaction value of the sale was $1,060,643.

13:51 EDT Goldman CEO says early feedback shows 'lots of interest' in Apple Card - Goldman Sachs CEO David Solomon is speaking on CNBC.

13:38 EDT Farfetch announces launch of flagship store on JD.com - Earlier, Farfetch Limited (FTCH) announced that it has launched a flagship store on JD.com (JD), which it notes is a strategic investor in Farfetch. This follows the acquisition of Toplife by Farfetch China announced in February this year. "Farfetch now has a 'Level 1' entry point on the JD.com app, providing JD.com's more than 300 million customers with instant access to more than 3,000 brands via Farfetch's network of more than 1,000 luxury brand and boutique partners. The partnership builds on the existing successful relationship between Farfetch and JD.com, started in July 2017," the company stated.

13:36 EDT Dropbox unveils new integrated workspace with updates to desktop experience - "Dropbox unveiled a new integrated workspace, the biggest user-facing change in the company's history. With updates to the Dropbox desktop experience, dropbox.com, and the mobile app, users get a single workspace designed to bring files, fragmented work tools, and teams together." The update includes early access to a new desktop app designed to provide a convenient new access point to the workspace. "Work has become scattered-files are spread across devices, in the cloud, and on our hard drives. We're working across multiple apps that don't talk to each other, and teams are struggling to keep up," said Drew Houston, CEO, Dropbox. "We're focused on removing the friction from that experience, pulling everything together in a way that nobody has done before. The new Dropbox helps you quiet the noise and find focus at work."

13:18 EDT Citi CFO sees Q2 investment banking revenue down in mid-teens range - Says Q2 investment banking revenue won't decline as much as the industry. Says Q2 FICC, equities revenue is down mid-single digits in Q2. CFO Mark Mason is speaking at the Morgan Stanley Financials Conference.

13:11 EDT PTC intends to increase target stock repurchases to 50% of annual free cash flow - In a regulatory filing, PTC announced its intention to increase its target stock repurchases from 40% of annual free cash flow to 50% of annual free cash flow for FY2020.

13:02 EDT CoStar Group names Michael Desmarais as chief human resources officer - CoStar Group announced the hire of Michael Desmarais to serve as the company's Chief Human Resources Officer. In this role, Desmarais is expected to be a valuable executive team member and a trusted advisor to the CEO and other senior leadership, the company said in a statement, adding that he will be tasked with "building and growing a top performing team and with ensuring CoStar has an engaged workforce and a dynamic, collaborative, performance driven culture that evolves as the company continues to grow."

12:47 EDT Morgan Stanley: U.S. could go into recession if trade war continues

12:34 EDT J&J announces results of new analysis from CREDENCE trial of Invokana - The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of a new subgroup analysis from the phase 3 CREDENCE study, showing Invokana significantly reduced the risk of major cardiovascular events and kidney failure in patients with type 2 diabetes and chronic kidney disease. These results were observed in patients taking Invokana, including those with CV risk factors but no history of CV disease and patients with history of CV disease, defined as a history of coronary, cerebrovascular or peripheral vascular disease. Results were presented today at the American Diabetes Association's 79th Scientific Sessions.

12:29 EDT Morgan Stanley 'highly confident' in reaching $4B-$5B in FICC revenue in '19

12:24 EDT Morgan Stanley CEO says would be 'surprised' if Q2 trading rev. beat Q1

12:24 EDT Morgan Stanley says may pursue deal for scale in fixed-income asset management

12:18 EDT Morgan Stanley CEO says wants bank unit to be 'much bigger'

12:09 EDT Morgan Stanley CEO says Solium deal offers access to 'sticky money' to manage - Says needs advisers to better use the technology the firm has developed. Sees a "lot of upside" to wealth management pretax margin. CEO James Gorman is speaking at the company's Financials Conference.

12:00 EDT Invitae falls -6.2% - Invitae is down -6.2%, or -$1.23 to $18.68.

12:00 EDT Azure Power falls -8.2% - Azure Power is down -8.2%, or -98c to $10.98.

12:00 EDT Enzo Biochem rises 12.8% - Enzo Biochem is up 12.8%, or 45c to $3.97.

11:49 EDT VW's Electrify America, Chargepoint partner to expand public EV charging access - Volkswagen's Electrify America and ChargePoint announced a roaming partnership that will further expand access to electric vehicle charging across the United States. The interoperability agreement will allow drivers to seamlessly charge their EVs on public chargers between both networks using their existing account credentials to start a session, without incurring any additional fees. Beginning later this year, drivers will be able to access public chargers on either the ChargePoint or Electrify America networks without having to create new memberships, registrations or payment configurations. The plan will connect more than 30,000 Level 2 and DC fast chargers from Electrify America and ChargePoint across the U.S., adding significant public access as the number of EVs on the road significantly increases in the coming years.

10:23 EDT State Street sees ongoing unit cost improvement up 5%-10% by 2020E - Says targeting about 230 applications to be rationalized in 2019. Says goal is to further rationalize an additional 5%-10% reduction in 2020. Sees continuing to drive ongoing unit cost improvement up 5%-10% by end of 2020. Comments from slides being presented at the Morgan Stanley Financials Conference.

10:00 EDT Azure Power falls -4.6% - Azure Power is down -4.6%, or -55c to $11.41.

10:00 EDT Argan falls -5.3% - Argan is down -5.3%, or -$2.33 to $41.50.

10:00 EDT Enzo Biochem rises 11.5% - Enzo Biochem is up 11.5%, or 41c to $3.92.

09:58 EDT Morgan Stanley Wealth Management head says client activity is muted

09:45 EDT Amcor completes acquisition of Bemis - Amcor (AMCRY) announces the completion of its acquisition of Bemis Company (BMS), effective June 11. The combined company will now operate as Amcor, trading on the New York Stock Exchange under the ticker symbol "AMCR." Amcor is included in both the S&P 500 and S&P/ASX 200 indices. Amcor CEO Ron Delia described the acquisition as "a significant milestone as two strong companies with histories each dating back over 150 years look forward to one great future. The acquisition of Bemis brings additional scale, capabilities and footprint that will strengthen Amcor's industry leading value proposition and generate significant value for shareholders."

09:43 EDT Jaguar Health soars after NIAID supports development of cholera treatment - Jaguar Health announced earlier today that its wholly-owned human-health subsidiary, Napo Pharmaceuticals, will receive preclinical services from the National Institute of Allergy and Infectious Diseases to support the development of lechlemer, Napo's drug product candidate for a cholera indication. Under NIAID's suite of preclinical services, NIAID-funded contractors will conduct toxicology testing for 7-day rat and dog studies, the comoany said in a statement. NIAID is part of the National Institutes of Health. Shares of Jaguar Health are up 87%, or $6.47, to $13.93 in early trading. "We are grateful for NIAID's support to conduct these preclinical animal studies of lechlemer," Lisa Conte, Jaguar's president and CEO, stated. "We believe lechlemer, which has the same mechanism of action as crofelemer and is significantly less costly to produce, may support efforts to receive a priority review voucher from the FDA for a cholera indication."

09:30 EDT Lazydays announces LOI to acquire Alliance Coach - Lazydays has announced that a Letter of Intent has been signed to acquire Alliance Coach. Located just outside Ocala, Florida, Alliance Coach is a premier RV dealership with strong brands such as Thor, Forest River, Holiday Rambler, Renegade and Vanleigh. The Alliance Coach dealership has a strong service presence, which fits well with Lazydays focus on service excellence and will enhance its service presence and operations in Florida. The acquisition of Alliance Coach is expected to be finalized in approximately 60 days. Upon closing, Alliance Coach will be rebranded as Lazydays RV of Central Florida. Lazydays operates six dealerships in Florida, Colorado, Arizona, Minnesota and Tennessee.

09:26 EDT Performance Shipping to acquire two Aframax tankers for $60M - Performance Shipping announced that it has agreed to acquire two entities, which have signed contracts to purchase two 2011-built Aframax tanker vessels from an unaffiliated third party seller for a total purchase price $60M. The transaction was unanimously approved by the disinterested members of the board of directors of the company. The company will acquire the two entities affiliated with the company's chairman and CEO Symeon Palios, for an aggregate purchase price of $10M, which will be paid in common shares of the Company at a per share price of $1.05, which is equal to the undiscounted closing price of the common stock on the NASDAQ stock exchange on June 7, 2019. The $10M purchase price of the two entities is equal to the deposit previously paid to the vessels' seller by the affiliates of the company's Chairman. The balance of the purchase price payable under the contracts is expected to be funded through cash on hand and bank financing. The first vessel delivery is expected in the third quarter of this year and the second in the fourth quarter. Following the closing of this transaction, the company will have 36,277,660 common shares and another 2,000 Series B-2 Preferred Shares issued and outstanding. Upon completion of the above-mentioned entities' acquisition, the company will own 4 unencumbered containerships, 2 contracts to purchase 2 Aframax tanker vessels, for which $10M have been paid as deposit, plus approximately $17M of cash.

09:18 EDT Euroseas announces closing of refinancing of two of its vessels - Euroseas announced that it has closed the previously announced refinancing of two of its vessels with simultaneous interest rate reduction of 0.5% for all other existing loans and the redemption of approximately $11.7M of value, or about 59.4%, of its outstanding Series B Preferred Shares with simultaneous reduction of 4% of the dividend rate for the $8M value of preferred shares remaining outstanding until January 2021. The closing of the above transactions reduced Euroseas' overall leverage of combined debt and preferred equity and reduced its interest and preferred dividend expenses by approximately $1.4M per year.

09:15 EDT LRAD Corporation announces $1.7M in Defense and Homeland Security orders - LRAD Corporation announced orders totaling $1.7M for multiple systems from government agencies in Japan, Southeast Asia and the United States Military. The orders include LRAD 100X MAG-HS kits and accessories for international deployment by the U.S. Military, LRAD 100X, LRAD 500X and LRAD 1000Xi systems under a follow-on homeland security order from Southeast Asia, and an LRAD 1000Xi systems order from Japan's Coast Guard awarded after extensive testing and a competitive tender.

09:14 EDT Land & Buildings issues letter to Taubman Centers shareholders - Land & Buildings sent the following letter to the shareholders of Taubman Centers: "...There are two key points that I took away from my tenure on the Board: 1. Taubman's 11 "Jewel Box1" assets are more productive, account for more of the value of the Company (in our view, the substantial majority of TCO) and are generating stronger net operating income (NOI) growth than we could have imagined. As such, we believe these assets are likely worth nearly double the current TCO share price based on property by property cap rates applied by a leading REIT research firm. 2. As I experienced firsthand, one independent shareholder voice in the boardroom was simply not enough to implement the changes necessary to drive shareholder value at Taubman. At next year's Annual Meeting of Shareholders (the "2020 Annual Meeting"), the Board will be fully de-staggered for the first time, which means that all directors will be up for re-election, including Chairman, President and Chief Executive Officer Bobby Taubman. We intend to continue to monitor the Company and take any action that we deem necessary to hold this Board and Bobby Taubman accountable at the 2020 Annual Meeting, including the nomination of director candidates. All directors and specifically, Bobby Taubman, can be held accountable by shareholders for the Company's atrocious absolute and relative performance for the first time since 2017 at the 2020 Annual Meeting. Their best defense against a proxy contest in 2020 is to drive material outperformance by maximizing value for all shareholders. Actions they can take include: 1. Exit Asia, which would likely drive nearly 10% accretion to annual earnings, materially reduce debt and eliminate future capital commitments for development. Blackstone's recent purchase of 50% of Taubman's Asia assets confirms both valuation and investor interest in these assets. Indeed, the Asia fully loaded returns were not as solid as disclosed and new projects in Asia will require more capital. 2. Sell or spin-off (think SITE Centers/Retail Value) the "Jewel Box" assets, which alone are likely worth nearly double the current share price applying property by property cap rates used by a leading REIT research firm. We believe the "Jewel Box" portfolio would be a must-own given the superior NOI growth, clean balance sheet, and fortress nature of the malls and would likely trade close to net asset value (NAV) (think premium brands like LVMH, Welltower, Federal Realty, Equity Residential, Prologis, etc.). The non-Jewel Box company (remain co) would have substantial cash flow, and material asset value as a standalone company. 3. Reverse a nearly decade long trend of meaningfully lowering forward consensus estimates - focus is shifting to beat and raise.I did not stand for re-election at the 2019 Annual Meeting because it was clear that the Company did not intend to re-nominate me for election to the Board. I decided not to run a proxy contest this year in order to let the Company focus on improvements and because Bobby Taubman, who I believe bears most of the responsibility for Taubman's terrible track record, was not up for election. However, shareholders are clearly disappointed with the actions the Board has taken - including in our view the decision to not re-nominate me - as the shares are down 14% and have underperformed Class A Mall Peers by 7% since the announcement.2 Accordingly, assuming no meaningful progress in the coming months, we intend to take action to hold this Board accountable at the 2020 Annual Meeting - including by nominating directors."

09:12 EDT Waddell & Reed appoints Dan Hanson as Chief Investment Officer - Waddell & Reed has named Daniel Hanson, CFA, as Chief Investment Officer, filling a "key role with a versatile industry veteran and prominent environmental, social and governance investor as the firm continues to position itself for future organic and inorganic growth." Hanson, who has more than 25 years of investment and leadership experience, is leading the firm's investment management division. He is also a member of the company's executive leadership team, reporting to CEO Philip Sanders, who had served as CIO since 2011.

09:10 EDT Inspired Entertainment enters into agreement to acquire NTG for $120M - Inspired Entertainment announced that it has entered into a definitive agreement to acquire the Gaming Technology Group, or NTG, of Novomatic UK, a division of Novomatic Group, a leading international supplier of gaming equipment and solutions, for the EUR equivalent of $120.0M in cash. Inspired is a leading supplier of Category B2/B3 gaming terminals in the UK, and NTG is a leading supplier of Category B3, C and D gaming terminals to pubs, arcades, motorway service areas and holiday resorts in the UK. Following the transaction, Inspired would be positioned to supply an extensive range of products and services across the UK and Europe, and beyond. Upon closing the acquisition, Inspired would manage more than 75,000 gaming machines in the UK and Europe.

09:09 EDT HomeStreet announces Glass Lewis recommendation for election of board nominees - HomeStreet announced that proxy advisory firm Glass Lewis has recommended that shareholders vote on the white proxy card for the election of all three of the company's nominees, Sandra Cavanaugh, Mark Mason and Donald Voss, to the board at the upcoming annual meeting of shareholders scheduled for June 20. Previously, proxy advisory firm Institutional Shareholder Services, or ISS, also recommended that shareholders vote on the white proxy card for the election of all three company nominees. Glass Lewis said, "Overall, we believe HomeStreet has demonstrated that it has a strong board that has presided over long-term shareholder value creation and is responsive to changing industry conditions and shareholder concerns."

09:06 EDT National Vision appoints Bill Clark as chief people officer - National Vision Holdings (EYE) announced that Bill Clark has joined the company as chief people officer, reporting to CEO Reade Fahs. In this newly created role, Clark will be responsible for leading, integrating and enhancing the human resources, training and organizational development functions and ensuring that National Vision continues to provide a strong company culture and experience allowing associates and optometrists to thrive. Clark comes to National Vision most recently from Five Below (FIVE) where he served as SVP of human resources. Clark will succeed SVP, chief human resources officer, Jeff Busbee, who is retiring from his role after having served National Vision for 24 years. Busbee will remain at the company for a period of time to help support Clark's transition into his new role.

09:04 EDT Fly Intel: Pre-market Movers - HIGHER: Broadcom (AVGO), up 4% after certain subsidiaries of the company entered into a statement of work with Apple (AAPL) providing for a supply arrangement for two years of new programs... New Age Beverages (NBEV), up 6% after Compass Point analyst Rommel Dionsio started shares with a Buy rating and $9 price target... Freeport-McMoRan (FCX), up 4% after CFO Kathleen Quirk disclosed the acquisition of 50,000 common shares of the company at a price of about $10.49 per share... NovaBay (NBY), up 35% as the company adds to yesterday's gains after announcing that Avenova Direct is available on Amazon.com (AMZN) through the company's new direct-to-consumer online channel... Lyft (LYFT), up 3% after Susquehanna analyst Shyam Patil upgraded the stock to Positive from Neutral and raised his price target for the shares to $80 from $57. DOWN AFTER EARNINGS: H&R Block (HRB), down 1%... Chico's (CHS), down 2%... HD Supply (HDS), down 7%. LOWER: CymaBay (CBAY), down 44% after announcing 12-week topline results from an ongoing 52-week Phase 2b study of seladelpar for the treatment of nonalcoholic steatohepatitis... Beyond Meat (BYND), down 11% after JPMorgan analyst Ken Goldman downgraded shares to Neutral from Overweight, stating that with the stock at around $168 seeing more upside "requires assumptions we are not yet comfortable with."... Symantec (SYMC), down 5% after Morgan Stanley analyst Keith Weiss downgraded the stock to Underweight from Equal Weight.

09:02 EDT Honeywell and Jaunt Air Mobility sign MOU to define solutions for eVTOL - Honeywell and Jaunt Air Mobility have signed a memorandum of understanding to define avionics, navigation, flight control, an electric propulsion system and connectivity solutions for Jaunt Air Mobility's planned electrical vertical takeoff and landing, or eVTOL, aircraft. This will be Honeywell's third collaboration with an air taxi company, assisting Jaunt Air Mobility with technology that will allow its air vehicles to interact safely and efficiently and help the company address regulatory and business challenges of the Urban Air Mobility segment. As part of the agreement, Honeywell and Jaunt Air Mobility will work together to develop the technical requirements, program statement of work and Definitive Agreement in support of Jaunt's eVTOL demonstration program by the fall of 2021.

09:01 EDT Bemis trading halted, news dissemination

08:40 EDT Tegna to acquire WTHR, WBNS for $535M from Dispatch Broadcast Group - Tegna announced it has entered into a definitive agreement with the Dispatch Broadcast Group to acquire, for $535M in cash, television stations WTHR, the NBC affiliate and the number one rated station in Indianapolis, Indiana and WBNS, the CBS affiliate and the number one rated station in Columbus, Ohio. Tegna is also acquiring WBNS Radio. Both television stations are the number one station in their respective markets. WTHR serves Indianapolis, which is Indiana's state capital and most populous city and the 28th largest television market in the United States. The city is home to major league teams and sports events like the Indianapolis 500, which air on NBC. WBNS serves Columbus, Ohio's state capital, which is the 34th largest television market. WBNS will join Tegna's WKYC, the NBC affiliate in Cleveland, and WTOL, the CBS affiliate in Toledo, in serving audiences and advertisers in Ohio, a political battleground state. Once the transaction concludes, Tegna stations will serve two-thirds of all television households in Ohio. The transaction, structured as a stock purchase, represents a purchase price multiple for the company of 7.9 times expected average 2018-2019 EBITDA, including run rate synergies. Tegna expects the transaction to be EPS accretive within a year after close and immediately accretive to free cash flow per share. Tegna will finance the transaction through the use of available cash and borrowing under its existing credit facility. Upon close, leverage is expected to increase to approximately 4.8 times, inclusive of the previously announced acquisition of the Nexstar-Tribune divestiture stations and the remaining portion of Cooper Media. Substantially all free cash flow will subsequently be used to reduce debt, reducing total leverage to approximately 4 times by the end of 2020.

08:38 EDT State Street signs LOI with Lazard Asset Management - State Street announced that it has entered into a letter of intent, or LOI, with Lazard Asset Management, or LAM, which, subject to entering into definitive agreements, will result in LAM adopting State Street's Front-to-Back investment servicing platform. "After definitive agreements are reached, LAM will become a member of the Charles River Development Client Advisory Board, which was established earlier this year, and now has 17 member firms globally."

08:34 EDT Celsius Holdings announces new launch with nationwide convenience store chain - Celsius Holdings announced a nationwide launch with a major premier convenience store chain in over 450 locations. The company said, "Under the agreement with our new customer QuikTrip, Celsius will be located on the top shelf of the energy door with a full shelf authorized in every market except AZ which will have a half shelf."

08:33 EDT Velan urges Progenics stockholders to vote against re-election - Velan Capital, one of the largest stockholders of Progenics Pharmaceuticals, announced that it has delivered a letter to stockholders expressing its concerns with the latest decision of the Progenics Board of Directors to further dilute stockholders, and providing clarity on certain misleading statements made by the Board. In the letter, Velan calls out the Board for its decision last week to dilute stockholders again by issuing equity. The Board issued 1.63M shares of Progenics common stock at approximately $4.20 per share for a milestone payment associated with its acquisition of AZEDRA. The Board chose to issue this dilutive equity rather than make this payment from its ample balance sheet cash reserves of ~$110M. Given the circumstances, Velan sees no rational reason to issue costly and undervalued equity. This situation is simple. The Board does not have stockholders' best interests at heart. Peter Crowley and Michael Kishbauch, the sole members of the Compensation Committee, own ZERO shares of common stock and support flawed corporate goals, which we believe incentivizes the dilution of stockholders for the personal gain of executives and directors. Change must occur to have true accountability and alignment with stockholders. We urge stockholders to vote AGAINST the re-election of Messrs. Crowley and Kishbauch on the GREEN proxy card.

08:31 EDT CVS Health announces availability of Vendor Benefit Management - CVS Health announced the availability of Vendor Benefit Management, a new service developed to help CVS Caremark pharmacy benefit management clients more easily contract, implement and manage their choice of available and emerging third-party health and wellness benefit solutions - both digital and non-digital. This new service offers clients a seamless way to access negotiated pricing, standardized member eligibility verification in real-time, simplified billing and payment processing, and standardized results measurement and reporting across multiple vendors. Big Health, a digital therapeutics company, is the first participating vendor, and Sleepio, its automated, personalized digital sleep improvement program, will be available to CVS Caremark clients via Vendor Benefit Management.

08:24 EDT Precision Therapeutics changes name to Predictive Oncology - Precision Therapeutics announced that it has changed its corporate name to Predictive Oncology Inc., which the Company believes best reflects the company's mission and strategic focus. The name change is effective immediately. In addition to its new corporate name, the Company expects that its common stock will trade under the new Nasdaq ticker symbol of POAI, effective on or about Thursday, June 13, 2019.

08:21 EDT AMD unveils new Radeon RX 5700 Series graphics card at E3 event - As reported last night, at the AMD "Next Horizon Gaming" livestream event at E3, the company unveiled its "next-generation PC gaming platform, bringing new levels of performance and efficiency and introducing powerful features for gamers everywhere, based on the new AMD Radeon RX 5700 Series graphics cards and 3rd Gen AMD Ryzen desktop processors. The AMD Radeon RX 5700 XT and RX 5700 graphics cards are built on the new AMD RDNA gaming architecture to deliver superior visual fidelity, lightning-fast performance and advanced features to power the latest AAA and eSports titles." The previously announced 3rd Gen Ryzen desktop processor family is expected to be available on July 7, 2019 from leading etailers/retailers. The AMD Radeon RX 5700 XT and RX 5700 graphics cards are expected to be generally available on July 7, 2019 for $449 and $379.

08:19 EDT ABM extends tenure as janitorial partner for Nationals Park - ABM has entered into an agreement to continue providing janitorial solutions for Nationals Park in Washington, D.C., home ballpark of the Nationals, the city's Major League Baseball team.

08:17 EDT LiveXLive Media report 20M livestream views in first two months of FY20 - LiveXLive Media announced that it delivered 20M livestream views across all its streamed events during the first two months of FY20, outpacing the FY19 livestream views of 51M. The next-generation subscription platform, which has livestreamed seven events this fiscal year, delivering live performances by 85 artists, and 125 hours of live music content, attributed its growth to the success of its newly-redesigned app, an increase in subscribers, and the addition of partnerships including its content and distribution agreement with iHeartMedia.

08:15 EDT Humana, Epic collaborate to provide more health information - Humana and Epic, a health record system, announced an agreement that will integrate technologies to enhance patient, provider and payer access to health information. Humana is the first national healthcare insurer to collaborate with Epic to bring together patients, providers and payers to power care. Humana and Epic are advancing interoperability to promote open communication and information transparency that will give patients and their practitioners integrated and real-time access to the patients' medical history, health insights and treatment options. To enhance the prescribers experience, Humana will integrate its real-time benefits check, or RTBC, tool, IntelligentRx, directly into Epic's e-prescribing workflow, delivering real-time pharmacy data throughout its network.

08:10 EDT H&R Block to acquire Wave Financial for $405M in cash - H&R Block announced that it entered into a definitive agreement to acquire Wave Financial, a financial solutions platform focused on changing the way small business owners manage their finances, for $405M in cash. Based in Toronto, Ontario, Wave is innovating and disrupting the small business market with free accounting, invoicing, and receipt-tracking software. Wave generates revenue by offering payment processing, payroll services, and bookkeeping services, with additional products currently in development. All of these products and services are offered through a comprehensive platform used by over 400,000 small businesses globally every month. The acquisition expands H&R Block's product and client portfolio and enhances its position in the small business market. It also provides new growth opportunities as Wave's disruptive pricing and low-cost customer acquisition model has resulted in rapid, organic growth. Under the terms of the agreement, H&R Block will acquire all outstanding shares of Wave for $405M, funded with available cash. The transaction is expected to close within the next few months, subject to regulatory approval and customary closing conditions. Based on the expected timing of closing, H&R Block estimates that the transaction will generate $40 to $45 million of revenue for fiscal 2020. The financial impact of this transaction is subject to the timing of the actual close of the transaction. Following the closing of the transaction, Wave will maintain its leadership team, including Kirk Simpson, operating independently within H&R Block from its headquarters in Toronto, Ontario.

08:05 EDT Ziopharm announces FDA clearance of IND for TCR-T cell therapy trial - Ziopharm Oncology announced that the investigational new drug application submitted by the National Cancer Institute has received clearance from the U.S. Food and Drug Administration for a clinical trial in solid tumors to evaluate T-cell receptor T-cell therapy utilizing Ziopharm's Sleeping Beauty platform. Ziopharm and the NCI are partnered in a cooperative research and development agreement, under the direction of Dr. Rosenberg, Chief of the Surgery Branch of the NCI, supporting clinical work to evaluate a non-viral approach to manufacturing TCR-T with the Sleeping Beauty platform that target solid tumors. With this approach, T cells can be genetically modified to express multiple, tumor-specific TCRs, which Ziopharm believes will be foundational technology to successfully targeting and treating metastatic solid tumors.

08:02 EDT Columbia Financial announces 4M share repurchase program - Columbia Financial announced that the company's Board of Directors has authorized a stock repurchase program to acquire up to 4M shares of the company's currently issued and outstanding common stock commencing on June 13. The stock repurchase program was adopted following the receipt of a notice of non-objection from the Federal Reserve Bank of Philadelphia.

07:59 EDT Agilent companion diagnostic receives expanded FDA approval in HNSCC - Agilent (A) announced that the FDA has approved its PD-L1 IHC 22C3 pharmDx assay for expanded use. The assay is now approved as an aid in identifying patients with head and neck squamous cell carcinoma, or HNSCC, for treatment with Keytruda, anti-PD-1 therapy manufactured by Merck (MRK). Keytruda, as a single agent, is indicated for the first-line treatment of patients with metastatic or with unresectable, recurrent HNSCC whose tumors express PD-L1 as determined by an FDA-approved test. PD-L1 IHC 22C3 pharmDx is the only companion diagnostic FDA-approved to aid in the identification of HNSCC patients for treatment with Keytruda. HNSCC is the fifth cancer type for which PD-L1 IHC 22C3 pharmDx has gained FDA approval in the United States.

07:35 EDT Motus GI Holdings receives FDA clearance to market second generation Pure-Vu - Motus GI Holdings announced it has received 510 clearance from the FDA for the second-generation Pure-Vu System to help facilitate the cleaning of a poorly prepared colon during the colonoscopy procedure.

07:32 EDT MediWound appoints Boaz Gur-Lavie as CFO - MediWound announced the appointment of Boaz Gur-Lavie as CFO effective June 11, 2019. Prior to joining MediWound, Gur-Lavie co-founded Center for Digital Innovation, a non-profit organization determined to improve the quality of lives by creating innovative new solutions for challenges in the space of healthy aging and digital health, while focusing on senior citizens.

07:27 EDT Chico's reports inventories totaled $242.4M at end of Q1 - At the end of the first quarter, inventories totaled $242.4M compared to $253.8M at the end of last year's first quarter. This $11.4M, or 4.5%, decrease primarily reflects the impact of product liquidations through a third party, store closures and management of inventory levels relative to net sales.

07:25 EDT Chico's CEO says 'made significant changes' to company leadership in Q1 - "In the first quarter, we made significant changes to the company's leadership and reset priorities for its growth and value creation," commented Bonnie Brooks, interim CEO and President of the company. "Actions are now underway across all brands with a focus on three distinct areas that will positively impact our results. These include driving stronger sales through improved product and marketing; optimizing the customer journey by simplifying, digitizing and extending our unique and personalized service; and transforming our sourcing and supply chain operations to increase product speed to market and improve quality. Having led successful turnarounds at other major apparel retailers, I am confident that our action steps on the path forward are the ones needed to deliver our plans."

07:19 EDT Iovance appoints Turning Point Therapeutics CEO Countouriotis to board - Iovance Biotherapeutics (IOVA) announced the appointment of Athena Countouriotis, M.D., to the company's Board of Directors, effective June 10, 2019. Countouriotis is the president and CEO of Turning Point Therapeutics (TPTX) and specialized in hematology and oncology in her professional career.

07:17 EDT Chico's reports Q1 SSS down 7% - The comparable sales decline was driven by lower average dollar sale and a decrease in transaction count.

07:14 EDT Deciphera, Zai Lab announce exclusive license agreement for ripretinib - Deciphera Pharmaceuticals (DCPH) and Zai Lab (ZLAB) announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China. Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumors driven by KIT or PDGFRalpha. Under the terms of the agreement, Deciphera will receive an upfront cash payment of $20M and will be eligible to receive up to $185M in potential development and commercial milestone payments. In addition, Zai Lab would pay Deciphera royalties from low to high teens on annual net sales of ripretinib in Greater China. Zai Lab receives exclusive regional development and commercialization rights for ripretinib in Greater China. Zai Lab plans to leverage its regulatory and clinical expertise to lead development of ripretinib in this territory. Deciphera intends to expand the ongoing global Phase 3 INTRIGUE study, comparing ripretinib to sunitinib in second-line GIST patients, and is currently assessing the addition of clinical trial sites in China.

07:12 EDT CymaBay reports topline 12-week data from ongoing Phase 2b study of seladelpar - CymaBay Therapeutics announced 12-week topline results from an ongoing 52-week Phase 2b dose-ranging, paired liver biopsy study of seladelpar for the treatment of nonalcoholic steatohepatitis. Seladelpar is a potent and selective peroxisome proliferator-activated receptor delta agonist currently in development for NASH and primary biliary cholangitis. The double-blind, placebo-controlled study randomized 181 subjects with biopsy-confirmed NASH and a liver fat content greater than 10% to receive either placebo or seladelpar 10 mg, 20 mg, or 50 mg once-daily. The enrolled subjects had established NASH with a mean NAFLD Activity Score of 5.2 at baseline, with 83% of subjects having stage 2 or stage 3 fibrosis. Other key baseline characteristics include a mean LFC by magnetic resonance imaging-proton density fat fraction of 21% as well as elevated mean ALT and AST levels of 62 U/L and 46 U/L, respectively. Approximately half of the subjects enrolled had a diagnosis of type 2 diabetes. The primary endpoint was the relative change in LFC from baseline to 12 weeks. The study remains blinded and will continue to 52 weeks with assessments including a liver biopsy, non-invasive imaging evaluations, and biomarker assessments of inflammation and fibrosis. Reductions in LFC as measured by MRI-PDFF at week 12 are highlighted in the table below. Treatment with seladelpar resulted in minimal reductions in liver fat that were not significant when compared to placebo. Treatment with seladelpar resulted in robust and clinically meaningful reductions in markers associated with liver injury as highlighted in the table below. Alanine aminotransferasedeclined up to 37.5% or 32 U/L in 12 weeks. These reductions in ALT are significantly greater than the 17 U/L threshold that has been correlated with histologic improvement in NASH. Gamma glutamyl transferase also decreased significantly, suggesting a reduction in hepatocellular oxidative stress. Significant reductions in alkaline phosphatase at 12 weeks were observed, supportive of a decrease in hepatocellular bile acids. The marked changes in these liver enzymes collectively suggest the potential to impact ballooning and lobular inflammation, the two key components of NASH resolution. Treatment with seladelpar also resulted in reductions in low-density lipoprotein cholesterol and triglycerides. At 12 weeks, the median percent changes in LDL-C were 7.8, -7.5, -8.4, and -14.4 in the placebo, seladelpar 10, 20, and 50 mg groups, respectively. The median percent change in triglycerides were 14.4, -9.1, -4.0, and -10.0 in the placebo, seladelpar 10, 20, and 50 mg groups, respectively. There were no significant changes in high-density lipoprotein cholesterol. High sensitivity C-reactive protein, a key marker of inflammation and cardiovascular risk, decreased by a greater magnitude in seladelpar-treated subjects, with median percent changes were -3.1, -16.7, -20.7, and -22.6 in the placebo, seladelpar 10, 20, and 50 mg groups, respectively. Seladelpar demonstrated a favorable safety and tolerability profile at all doses evaluated in this study. The most common treatment emergent adverse events included nausea, constipation, dizziness, headache, gastroesophageal reflux disease and upper abdominal pain. The majority of treatment emergent adverse events were mild to moderate in severity and deemed unrelated to study drug. There were two serious adverse events that occurred after randomization through week 12, neither of which were deemed to be related to study drug.

07:09 EDT Deciphera, Zai Lab announce ripretinib license agreement in Greater China - Deciphera (DCPH) and Zai Lab (ZLAB) announced an exclusive license agreement to advance the development and commercialization of ripretinib in Greater China. Discovered and developed by Deciphera, ripretinib is an investigational, oral, kinase switch control inhibitor in clinical development for the treatment of GIST and other solid tumors driven by KIT or PDGFRa. Under the terms of the agreement, Deciphera will receive an upfront cash payment of $20M and will be eligible to receive up to $185M in potential development and commercial milestone payments. In addition, Zai Lab would pay Deciphera royalties from low to high teens on annual net sales of ripretinib in Greater China. Zai Lab receives exclusive regional development and commercialization rights for ripretinib in Greater China. Zai Lab plans to leverage its regulatory and clinical expertise to lead development of ripretinib in this territory. Deciphera intends to expand the ongoing global Phase 3 INTRIGUE study, comparing ripretinib to sunitinib in second-line GIST patients, and is currently assessing the addition of clinical trial sites in China.

07:07 EDT Wells Fargo announces sale of Eastdil Secured, terms not disclosed - Wells Fargo announced the sale of Eastdil Secured, its private real estate investment banking division. This follows Eastdil's management-led recapitalization, in partnership with Guggenheim Investments, on behalf of certain institutional clients, and Temasek, a global investment company headquartered in Singapore. Subsequent to the sale, Wells Fargo will retain the public market real estate investment bankers of Eastdil, who will form the Real Estate, Gaming, Lodging, and Leisure industry coverage group within Corporate & Investment Banking. Additionally, Wells Fargo will retain a minority ownership interest in Eastdil. Pending regulatory approvals, the transaction is expected to close in Q4. Terms of the transaction have not been disclosed.

07:06 EDT Zynerba receives U.S. patent for treatment of autism spectrum disorder with CBD - Zynerba Pharmaceuticals announced that the U.S. Patent and Trademark Office has issued US Patent No. 10,314,792, titled "Treatment of Autism Spectrum Disorder with Cannabidiol" which includes claims directed to methods of treating autism spectrum disorder by administering a therapeutically effective amount of synthetic cannabidiol. This new patent, which expires in 2038, is part of an expanding intellectual property portfolio covering the Company's cannabidiol product candidate, Zygel. This patent follows the previously announced issuance of US Patent No. 10,213,390, titled "Treatment of Fragile X Syndrome with Cannabidiol" which includes claims directed to methods of treating Fragile X Syndrome by administering a therapeutically effective amount of synthetic or purified cannabidiol. The issuance of this patent comes as enrollment progresses in the open label Phase 2 BRIGHT study evaluating the safety, tolerability and efficacy of Zygel for the treatment of children and adolescents with Autism Spectrum Disorder. The efficacy assessments include the Aberrant Behavior Checklist, Parent Rated Anxiety Scale - Autism Spectrum Disorder, Autism Impact Measure, and Clinical Global Impression - Severity and Improvement. The Company expects to report top line data in the first half of 2020.

07:05 EDT Chili's partners exclusively with DoorDash - Brinker International, the parent company of Chili's and Maggiano's Little Italy, has entered into an exclusive agreement with DoorDash, the nation's largest on-demand destination for door-to-door delivery, that brings delivery of Chili's favorites to Guests from more than 1,000 participating restaurants nationwide. Chili's expects its national partnership with DoorDash to accelerate its omnichannel leadership, drive continued sales growth by levelling the convenience playing field with fast casual and quick service restaurants, and further strengthen the brand for the next generation of guests.

07:04 EDT Nova Lifestyle announces $2M share repurchase program - Nova LifeStyle announced that, on June 4, 2019, its Board of Directors has approved and authorized an 10b-18 share repurchase program for the company to repurchase up to $2M shares of its common stock in transactions conducted through a broker or dealer in compliance with Rule 10b-18 promulgated under the Exchange Act. Nova LifeStyle intends to fund the repurchases from its more than $40M existing cash balance.

07:02 EDT Achieve Life Sciences announces results from ORCA-1 trial of cytisinicline - Achieve Life Sciences announced positive results from the ORCA-1 dose-selection trial of cytisinicline for smoking cessation. The outcome of the 254-subject, ORCA-1 trial is the selection of 3.0 mg, three times daily, or TID, for Phase 3 development. The primary endpoint was the reduction in daily smoking, a self-reported measure. Across all treatment arms, over the 25-day treatment period, subjects on cytisinicline experienced a 74-80% median reduction in the number of cigarettes smoked, compared to a 62% reduction in the placebo arms. The secondary endpoint of the trial was a 4-week continuous abstinence rate, which is the relevant endpoint for regulatory approval. Cytisinicline treatment showed significant improvements in abstinence rates compared to placebo. The Company expects to conduct further analyses of the ORCA-1 trial and submit data for presentation at a future medical meeting. Additionally, Achieve plans to discuss the trial's outcome with the FDA and finalize Phase 3 protocol details in the second-half of 2019.

06:55 EDT Achieve Life Sciences Inc trading halted, news pending

06:43 EDT Legacy Reserves reaches agreement on terms of financial restructuring - Legacy Reserves announced that its board of directors has approved, and the company has executed, a restructuring support agreement with its lenders under its reserve based revolving credit facility and its lenders under its second lien term loan. The proposed financial restructuring would reduce the company's debt, provide access to additional capital and establish a more sustainable capital structure. To facilitate the financial restructuring and implement the pre-arranged plan of reorganization contemplated by the restructuring agreement, the company expects to file voluntary petitions for reorganization in the United States Bankruptcy Court for the Southern District of Texas pursuant to chapter 11 of the United States Bankruptcy Code. The plan, which the RBL lenders and second lien lenders have agreed to support, will provide for de-leveraging of the company's capital structure by over $900M, including an infusion of at least $200M in equity capital through a rights offering and a committed equity backstop and payment in full of the company's other secured creditors, tax and other priority claimants, trade creditors and employees. Consummation of the plan, including the infusion of new equity, will be subject to confirmation by the court in addition to other conditions to be set forth in the plan and related transaction documents. The plan is expected to be filed within 30 days following the commencement of the chapter 11 cases. The company is also in active discussions with the advisors for a group of the company's noteholders regarding terms for their support of the restructuring agreement. The company will continue to operate its business in the normal course without material disruption to its vendors, partners or employees, and expects to have sufficient liquidity to meet its financial obligations during the restructuring. The restructuring agreement contemplates that the company will obtain debtor-in possession, or DIP, financing provided by certain of its existing RBL lenders. The DIP financing, subject to court approval, will refinance portions of the company's existing reserve-based credit facility and provide an additional $100M in new money to support the company's day-to-day operations and finance the restructuring process. The restructuring agreement further provides that, upon confirmation of the plan and emergence from chapter 11, the company will obtain access to a senior secured asset-based lending credit facility in a maximum amount of $500M provided by certain of the existing RBL lenders.

06:06 EDT Mesoblast and JCR Pharma expand partnership in Japan to the use of MSCs - Mesoblast announced it has expanded its partnership with JCR Pharmaceuticals in Japan to the use of mesenchymal stem cells, or MSCs, for the treatment of newborns who lack sufficient blood supply and oxygen to the brain, a condition termed neonatal hypoxic ischemic encephalopathy, or HIE. JCR is marketing the allogeneic MSC product TEMCELL 4 HS Inj. for the treatment of steroid-refractory acute graft versus host disease, or aGVHD, in children and adults in Japan. Under the terms of the partnership, Mesoblast receives royalties on TEMCELL product sales for all licensed indications. The license agreement was previously expanded for use in wound healing in patients with Epidermolysis Bullosa, or EB, and JCR filed to extend marketing approval of TEMCELL in Japan for this indication in March 2019. The license agreement has now been further expanded to provide JCR with rights to sell TEMCELL for HIE and to access Mesoblast's broad patent portfolio for this indication. JCR plans to initiate a clinical trial of TEMCELL in newborns with HIE in July 2019 in order to further extend the label in this indication. Mesoblast has the right to use all safety and efficacy data generated by JCR in Japan to support its development and commercialization plans for its MSC product candidate remestemcel-L in the U.S. and other major healthcare markets, including for GVHD, wound healing, and now HIE.

06:02 EDT Gap signs partnership with Arvind to open new innovation center - Gap announced a new partnership with its sourcing and franchise partner in India, Arvind. The apparel industry is one of the most intensive users of water in the world and, in India, 54% of the population faces high to extremely high water risk. The two companies will open a new innovation center to promote the adoption of proven techniques and technology that reduce water use by the textile manufacturing industry. Further, Arvind and Gap are also investing in a new water treatment facility that will eliminate the use of fresh water at Arvind's denim mill in Ahmedabad, India. The facility will save three billion liters of fresh water by the end of 2020 and preserve the local community's vital freshwater resources.

05:27 EDT Alibaba A.I. Labs announces partnerships with Honda, Renault - Alibaba A.I. Labs, an AI research division of Alibaba Group, today announced at CES Asia partnerships with auto brands, including Audi, Renault and Honda to drive a smart mobility initiative in China. Tmall Genie Auto, an Artificial Intelligence solution developed by Alibaba A.I. Labs, will be integrated into the automakers' specific internet cars in China. Owners of the three auto brands' specific-model vehicles equipped with Tmall Genie Auto will have access to a wide variety of voice-controlled information and services in the near future; these include identifying nearby attractions and restaurants, booking movie tickets, ordering to-go boxes, checking the status of package deliveries, reading children's books and ordering items on Alibaba's retail platform.